A phase 2, open-label, multicenter study of INCAGN01876 (anti-GITR agonist) in combination with retifanlimab (anti-PD-1) in recurrent or metastatic head and neck squamous cell carcinoma
INCAGN-01876;Retifanlimab
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: A phase 2, open-label, multicenter study of INCAGN01876 (anti-GITR agonist) in combination with retifanlimab (anti-PD-1) in recurrent or metastatic head and neck squamous cell carcinoma ### Output: INCAGN-01876;Retifanlimab